Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Other Working Capital Changes (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Other Working Capital Changes for 10 consecutive years, with $334000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes rose 147.24% to $334000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 388.36% increase, with the full-year FY2024 number at -$48000.0, changed N/A from a year prior.
  • Other Working Capital Changes was $334000.0 for Q3 2025 at Rein Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $2.1 million in Q4 2024 to a low of -$1.5 million in Q4 2022.
  • A 5-year average of $23127.4 and a median of -$31000.0 in 2022 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: crashed 668.54% in 2022, then soared 2404.3% in 2024.
  • Rein Therapeutics' Other Working Capital Changes stood at $267000.0 in 2021, then plummeted by 668.54% to -$1.5 million in 2022, then skyrocketed by 93.87% to -$93000.0 in 2023, then skyrocketed by 2404.3% to $2.1 million in 2024, then crashed by 84.41% to $334000.0 in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Other Working Capital Changes are $334000.0 (Q3 2025), $2.1 million (Q4 2024), and -$707000.0 (Q3 2024).